{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:33:14Z","timestamp":1791509594536,"version":"4.3.4"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether the quantity of psychological therapy is associated with symptom reduction in PAT for depressive symptoms.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, PsycINFO, and Scopus databases were searched from inception to June 16, 2025.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n The analysis included controlled clinical trials involving adults with depressive symptoms who received PAT using classic serotonergic psychedelics (eg, psilocybin or lysergic acid diethylamide). Within these trials, psychedelic dosing sessions were embedded in therapeutic sessions before (preparation) and after (integration). Studies were excluded if they used microdosing as the primary intervention, involved naturalistic or purely pharmacological administration, or did not report therapy session count or duration. Qualitative studies, reviews, case reports, and conference abstracts were also excluded. Of the 226 records identified, 42 full texts were assessed by 2 independent reviewers, of which 12 met inclusion criteria.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two reviewers independently extracted data and assessed risk of bias according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Multilevel random-effects meta-analysis and multilevel metaregressions were conducted using robust variance estimation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcomes were standardized mean differences (Hedges\n g<\/jats:italic>\n ) in depressive symptoms at all available posttreatment time points. Metaregression analyses assessed associations of different metrics of psychological therapy quantity (duration in hours, number of sessions, and total duration in weeks) with treatment outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The 12 included trials had a total sample of 733 participants (365 female [49.8%]; mean [SD] age, 43.1 [6.2] years). PAT showed a large overall effect size in reducing depressive symptoms compared with control conditions (Hedges\n g<\/jats:italic>\n \u2009=\u2009\u22120.84; 95% CI, \u22121.15 to \u22120.54;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). More preparation therapy hours were significantly associated with greater symptom reduction (\u03b2\u2009=\u2009\u22120.13; 95% CI, \u22120.24 to \u22120.01;\n P<\/jats:italic>\n \u2009=\u2009.04). No significant associations were found for hours of postdosing integration (\u03b2\u2009=\u2009\u22120.02; 95% CI, \u22120.08 to 0.05;\n P<\/jats:italic>\n \u2009=\u2009.53) or total session count (\u03b2\u2009=\u2009\u22120.01; 95% CI, \u22120.09 to \u22120.08;\n P<\/jats:italic>\n \u2009=\u2009.86). Longer follow-up periods, measured in weeks from substance administration, were generally associated with smaller treatment effect sizes (\u03b2\u2009=\u20090.02; 95% CI, 0.01 to 0.04;\n P<\/jats:italic>\n \u2009=\u2009.003). Risk of bias was high in the majority (9 [75%]) of studies, mostly due to ineffective blinding.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and meta-analysis of controlled clinical trials investigating PAT for depressive symptoms, a greater quantity of preparation therapy was associated with significantly larger reductions of depressive symptoms. These findings highlight a potential key role of preparation in optimizing PAT outcomes. The observed association primarily reflects quantitative aspects of therapy exposure rather than qualitative or process-related dimensions of the therapeutic interaction. Additional systematic research is needed to clarify this association and optimize all therapeutic components within psychedelic interventions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.54843","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:30Z","timestamp":1769011230000},"page":"e2554843","source":"Crossref","is-referenced-by-count":14,"title":["Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy"],"prefix":"10.1001","volume":"9","author":[{"given":"Gianluca Andri","family":"Florineth","sequence":"first","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"},{"name":"Graduate School for Health Sciences, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Klima","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Laura","family":"Boeker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (UPK), University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Catzeflis","sequence":"additional","affiliation":[{"name":"S\u00fcdhang Clinic, Kirchlindach, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wopfner","sequence":"additional","affiliation":[{"name":"S\u00fcdhang Clinic, Kirchlindach, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Denier","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bracht","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Adorjan","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pfammatter","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry (UPK), University of Basel, Basel, Switzerland"},{"name":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila Maria","family":"Soravia","sequence":"additional","affiliation":[{"name":"Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"11","key":"zoi251462r2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"15","key":"zoi251462r3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi251462r4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi251462r5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"zoi251462r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100725","article-title":"Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial.","volume":"6","author":"M\u00fcller","year":"2025","journal-title":"Med"},{"issue":"6","key":"zoi251462r8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"issue":"4","key":"zoi251462r9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy.","volume":"74","author":"Horton","year":"2021","journal-title":"Am J Psychother"},{"issue":"3","key":"zoi251462r10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1037\/pst0000551","article-title":"A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.","volume":"62","author":"Palitsky","year":"2025","journal-title":"Psychotherapy (Chic)"},{"issue":"1","key":"zoi251462r11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi251462r12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1176\/appi.ajp.20230661","article-title":"Misinterpretations and omissions: a critical response to Goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy.","volume":"181","author":"O\u2019Donnell","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi251462r13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/02698811241309611","article-title":"A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.","volume":"39","author":"Roseman","year":"2025","journal-title":"J Psychopharmacol"},{"issue":"6","key":"zoi251462r14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamapsychiatry.2025.0442","article-title":"Issues in clinical trial design-lessons from the FDA\u2019s rejection of MDMA.","volume":"82","author":"Wilkinson","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"71","key":"zoi251462r15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"zoi251462r17","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251381074","article-title":"Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.","volume":"15","author":"Muthumaraswamy","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"zoi251462r18","doi-asserted-by":"publisher","first-page":"d4829","DOI":"10.1136\/bmj.d4829","article-title":"Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study.","volume":"343","author":"Tendal","year":"2011","journal-title":"BMJ"},{"key":"zoi251462r19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"zoi251462r20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"449","key":"zoi251462r21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/01621459.2000.10473905","article-title":"Nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis.","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"zoi251462r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi251462r23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jrsm.5","article-title":"Robust variance estimation in meta-regression with dependent effect size estimates.","volume":"1","author":"Hedges","year":"2010","journal-title":"Res Synth Methods"},{"issue":"3","key":"zoi251462r24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11121-021-01246-3","article-title":"Meta-analysis with robust variance estimation: expanding the range of working models.","volume":"23","author":"Pustejovsky","year":"2022","journal-title":"Prev Sci"},{"issue":"1","key":"zoi251462r25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","article-title":"Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study.","volume":"21","author":"Geissb\u00fchler","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"zoi251462r26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"12","key":"zoi251462r27","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"5","key":"zoi251462r28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi251462r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi251462r30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial.","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"3","key":"zoi251462r31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study.","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"3","key":"zoi251462r32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin.","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"12","key":"zoi251462r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial.","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi251462r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112749","article-title":"The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis.","volume":"284","author":"Goldberg","year":"2020","journal-title":"Psychiatry Res"},{"key":"zoi251462r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115531","article-title":"Psilocybin-assisted therapy for depression: a systematic review and meta-analysis.","volume":"329","author":"Haikazian","year":"2023","journal-title":"Psychiatry Res"},{"key":"zoi251462r36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis.","volume":"322","author":"Ko","year":"2023","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi251462r37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/acps.13778","article-title":"Randomized controlled trials of psilocybin-assisted therapy in the treatment of major depressive disorder: systematic review and meta-analysis.","volume":"151","author":"Menon","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"zoi251462r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"zoi251462r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10503309712331331843","article-title":"Research-informed psychotherapy.","volume":"7","author":"Grawe","year":"1997","journal-title":"Psychother Res"},{"issue":"4","key":"zoi251462r40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000546270","article-title":"In psychedelic-assisted therapy, the alliance in the psychotherapy component is as important as the drug.","volume":"94","author":"Fl\u00fcckiger","year":"2025","journal-title":"Psychother Psychosom"},{"issue":"6","key":"zoi251462r41","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1037\/rev0000589","article-title":"Common factors in altered states: understanding psychedelic therapy through the lens of Grawe\u2019s general change mechanisms.","volume":"132","author":"Wolff","year":"2025","journal-title":"Psychol Rev"},{"issue":"4","key":"zoi251462r42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1037\/pst0000175","article-title":"Therapist empathy and client outcome: an updated meta-analysis.","volume":"55","author":"Elliott","year":"2018","journal-title":"Psychotherapy (Chic)"},{"issue":"5","key":"zoi251462r43","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpp.2864","article-title":"Growth curves of common factors in psychotherapy: multilevel growth modelling and outcome analysis.","volume":"30","author":"Meier","year":"2023","journal-title":"Clin Psychol Psychother"},{"issue":"4","key":"zoi251462r44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/10503301003796839","article-title":"Goal setting in psychotherapy: the relevance of approach and avoidance goals for treatment outcome.","volume":"20","author":"Wollburg","year":"2010","journal-title":"Psychother Res"},{"issue":"3","key":"zoi251462r45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/02698811211073758","article-title":"The Acceptance\/Avoidance-Promoting Experiences Questionnaire (APEQ): a theory-based approach to psychedelic drugs\u2019 effects on psychological flexibility.","volume":"36","author":"Wolff","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"7","key":"zoi251462r48","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context.","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"zoi251462r49","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review.","volume":"13","author":"Ko","year":"2022","journal-title":"Front Psychiatry"},{"key":"zoi251462r50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106086","article-title":"The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis.","volume":"172","author":"Romeo","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"zoi251462r51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.genhosppsych.2025.07.020","article-title":"A dose of therapy with psilocybin - a meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy.","volume":"96","author":"Hultgren","year":"2025","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"zoi251462r52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/10503307.2019.1566676","article-title":"The dose-response effect in routinely delivered psychological therapies: a systematic review.","volume":"30","author":"Robinson","year":"2020","journal-title":"Psychother Res"},{"issue":"4","key":"zoi251462r53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1037\/pst0000172","article-title":"The alliance in adult psychotherapy: a meta-analytic synthesis.","volume":"55","author":"Fl\u00fcckiger","year":"2018","journal-title":"Psychotherapy (Chic)"},{"key":"zoi251462r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114297","article-title":"A systematic review and meta-analysis of the success of blinding in antidepressant RCTs.","volume":"307","author":"Scott","year":"2022","journal-title":"Psychiatry Res"},{"issue":"1","key":"zoi251462r55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S2215-0366(24)00333-X","article-title":"Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.","volume":"12","author":"Seybert","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"zoi251462r56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/sim.1023","article-title":"Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head.","volume":"21","author":"Berlin","year":"2002","journal-title":"Stat Med"},{"issue":"5","key":"zoi251462r57","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/02698811241249698","article-title":"Measuring psychotherapeutic processes in the context of psychedelic experiences: validation of the General Change Mechanisms Questionnaire (GCMQ).","volume":"38","author":"Wolff","year":"2024","journal-title":"J Psychopharmacol"},{"key":"zoi251462r16","first-page":"3","volume-title":"Disruptive Psychopharmacology","author":"Liechti","year":"2022"},{"key":"zoi251462r46","first-page":"1","volume-title":"Current Topics in Behavioral Neurosciences","author":"Hartogsohn","year":"2024"},{"key":"zoi251462r47","volume-title":"Psychological Therapy","author":"Grawe","year":"2004"},{"key":"zoi251462r1","unstructured":"World Health Organization. Global health estimates: depression and other common mental disorders. 2017. Accessed June 12, 2025. https:\/\/policycommons.net\/artifacts\/546082\/depression-and-other-common-mental-disorders\/1523689\/"},{"key":"zoi251462r7","doi-asserted-by":"crossref","unstructured":"Guss? J, Krause? R, Sloshower? J. The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame).? PsyArXiv. Preprint posted online August 13, 2020. doi:10.31234\/osf.io\/u6v9y","DOI":"10.31234\/osf.io\/u6v9y"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844126\/florineth_2026_oi_251462_1768335150.56051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:32Z","timestamp":1769011232000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844126"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.54843","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}